Title |
Natalizumab for relapsing remitting multiple sclerosis
|
---|---|
Published in |
Cochrane database of systematic reviews, October 2011
|
DOI | 10.1002/14651858.cd007621.pub2 |
Pubmed ID | |
Authors |
Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj, Ian Galea |
Abstract |
Natalizumab (NTZ) (Tysabri(®)) is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier, thus reducing inflammation in central nervous system, and has been approved worldwide for the treatment of relapsing-remitting multiple sclerosis (RRMS). |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 23% |
Montenegro | 1 | 8% |
Spain | 1 | 8% |
France | 1 | 8% |
Unknown | 7 | 54% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 13 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 348 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | <1% |
Brazil | 2 | <1% |
Chile | 1 | <1% |
Italy | 1 | <1% |
Sri Lanka | 1 | <1% |
United Kingdom | 1 | <1% |
Unknown | 340 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 55 | 16% |
Student > Bachelor | 35 | 10% |
Researcher | 34 | 10% |
Student > Ph. D. Student | 33 | 9% |
Student > Doctoral Student | 22 | 6% |
Other | 55 | 16% |
Unknown | 114 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 111 | 32% |
Nursing and Health Professions | 23 | 7% |
Psychology | 23 | 7% |
Agricultural and Biological Sciences | 10 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 3% |
Other | 43 | 12% |
Unknown | 128 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2020.
All research outputs
#1,150,287
of 25,461,852 outputs
Outputs from Cochrane database of systematic reviews
#2,361
of 12,090 outputs
Outputs of similar age
#4,912
of 144,905 outputs
Outputs of similar age from Cochrane database of systematic reviews
#14
of 131 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,090 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.2. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 144,905 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 131 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.